Delivering precision oncology to patients with cancer
With the increasing use of genomic profiling for diagnosis and therapy guidance in many
tumor types, precision oncology is rapidly reshaping cancer care. However, the current …
tumor types, precision oncology is rapidly reshaping cancer care. However, the current …
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - Molecular cancer, 2018 - Springer
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung cancer
H Borghaei, S Gettinger, EE Vokes… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Immunotherapy has revolutionized the treatment of advanced non–small-cell
lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057) …
lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057) …
Perioperative ctDNA-based molecular residual disease detection for non–small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1)
Purpose: We assessed whether perioperative circulating tumor DNA (ctDNA) could be a
biomarker for early detection of molecular residual disease (MRD) and prediction of …
biomarker for early detection of molecular residual disease (MRD) and prediction of …
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open …
Background The oligometastatic paradigm suggests that some patients with a limited
number of metastases might be cured if all lesions are eradicated. Evidence from …
number of metastases might be cured if all lesions are eradicated. Evidence from …
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
MD Hellmann, TE Ciuleanu, A Pluzanski… - … England Journal of …, 2018 - Mass Medical Soc
Background Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–
small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has …
small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has …
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
SJ Antonia, A Villegas, D Daniel… - … England Journal of …, 2017 - Mass Medical Soc
Background Most patients with locally advanced, unresectable, non–small-cell lung cancer
(NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy …
(NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy …
[HTML][HTML] Early lung cancer diagnostic biomarker discovery by machine learning methods
Early diagnosis has been proved to improve survival rate of lung cancer patients. The
availability of blood-based screening could increase early lung cancer patient uptake. Our …
availability of blood-based screening could increase early lung cancer patient uptake. Our …
Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling
Identifying molecular residual disease (MRD) after treatment of localized lung cancer could
facilitate early intervention and personalization of adjuvant therapies. Here, we apply cancer …
facilitate early intervention and personalization of adjuvant therapies. Here, we apply cancer …
Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors
HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers.
We assessed the safety/tolerability and activity of the novel HER2-targeted antibody–drug …
We assessed the safety/tolerability and activity of the novel HER2-targeted antibody–drug …